Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors

Trial Profile

Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2016 Planned number of patients changed from 20 to 10.
    • 15 Dec 2016 Planned number of patients changed from 10 to 20.
    • 17 May 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top